أعرض في EDS

PB1701 OR21, A NEWLY ORAL DECITABINE PRODRUG, HAS ANTI-TUMOR EFFECT AGAISNT MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA VIA CELL DIFFERENTIATION INDUCED BY UP-REGULATION OF CEBPE

التفاصيل البيبلوغرافية
العنوان:	PB1701 OR21, A NEWLY ORAL DECITABINE PRODRUG, HAS ANTI-TUMOR EFFECT AGAISNT MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA VIA CELL DIFFERENTIATION INDUCED BY UP-REGULATION OF CEBPE
المؤلفون:	T. Watanabe, K. Tohyama, T. Ushijima, H. Ureshino, K. Kamachi, Y. Kurahashi, Y. Fukuda-Kurahashi, S. Okada, S. Kimura
المصدر:	HemaSphere. 3:783-784
بيانات النشر:	Ovid Technologies (Wolters Kluwer Health), 2019.
سنة النشر:	2019
مصطلحات موضوعية:	Antitumor activity, Downregulation and upregulation, business.industry, Cellular differentiation, Cancer research, Myeloid leukemia, Medicine, Decitabine, Hematology, CEBPE, Prodrug, business, medicine.drug
تدمد:	2572-9241
URL الوصول:	https://explore.openaire.eu/search/publication?articleId=doi_________::e336e6728859ace8e2d3bca48ef7bc94 https://doi.org/10.1097/01.hs9.0000565320.82707.5e
حقوق:	OPEN
رقم الأكسشن:	edsair.doi...........e336e6728859ace8e2d3bca48ef7bc94
قاعدة البيانات:	OpenAIRE

الوصف
تدمد:	25729241